[{"id":"7b548fc7-aa2b-4406-a054-9b2f242954f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06850285","created_at":"2025-03-03T10:01:00.133Z","updated_at":"2025-03-03T10:01:00.133Z","phase":"","brief_title":"CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma","source_id_and_acronym":"NCT06850285","lead_sponsor":"Shanxi Bethune Hospital","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 09/05/2025","start_date":" 09/05/2025","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-27"},{"id":"c668d4a7-2db9-4659-a308-7bc585eaa55d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02917083","created_at":"2021-01-18T14:19:13.880Z","updated_at":"2025-02-25T16:44:02.059Z","phase":"Phase 1","brief_title":"CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)","source_id_and_acronym":"NCT02917083","lead_sponsor":"Baylor College of Medicine","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TT11 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/08/2017","start_date":" 05/08/2017","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 02/01/2040","study_completion_date":" 02/01/2040","last_update_posted":"2025-02-05"},{"id":"e7d829bd-de22-4969-85f4-ae3c9695ba2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06090864","created_at":"2025-02-25T17:02:58.123Z","updated_at":"2025-02-25T17:02:58.123Z","phase":"Phase 1/2","brief_title":"ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells","source_id_and_acronym":"NCT06090864","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8 • CCR4","pipe":"","alterations":" ","tags":["TNFRSF8 • CCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • TT11 • ATLCAR.CD30.CCR4 cells"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 04/25/2024","start_date":" 04/25/2024","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2031","study_completion_date":" 07/01/2031","last_update_posted":"2025-02-03"},{"id":"ea7acd25-7f5f-485b-920f-36c4074db856","acronym":"","url":"https://clinicaltrials.gov/study/NCT06617286","created_at":"2025-02-26T10:28:12.676Z","updated_at":"2025-02-26T10:28:12.676Z","phase":"Phase 1/2","brief_title":"CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma","source_id_and_acronym":"NCT06617286","lead_sponsor":"New York Medical College","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/31/2039","primary_completion_date":" 12/31/2039","study_txt":" Completion: 12/31/2040","study_completion_date":" 12/31/2040","last_update_posted":"2024-10-18"},{"id":"63409644-83e7-4992-90f5-2ef1af04c65d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06532643","created_at":"2025-02-25T20:21:51.680Z","updated_at":"2025-02-25T20:21:51.680Z","phase":"Phase 1","brief_title":"Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma","source_id_and_acronym":"NCT06532643","lead_sponsor":"Shanghai First Song Biotechnology Co., LTD","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 08/24/2023","start_date":" 08/24/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-09-19"},{"id":"1bee75b3-9c2d-44df-aa38-d77483458e28","acronym":"","url":"https://clinicaltrials.gov/study/NCT02690545","created_at":"2021-01-17T17:19:13.271Z","updated_at":"2024-07-02T16:35:08.192Z","phase":"Phase 1/2","brief_title":"Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL","source_id_and_acronym":"NCT02690545","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11 • ATLCAR.CD30 cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/26/2016","start_date":" 08/26/2016","primary_txt":" Primary completion: 08/26/2025","primary_completion_date":" 08/26/2025","study_txt":" Completion: 08/26/2040","study_completion_date":" 08/26/2040","last_update_posted":"2024-04-23"},{"id":"1e1f1982-bd28-4ad1-b264-11dd83d52229","acronym":"","url":"https://clinicaltrials.gov/study/NCT02663297","created_at":"2021-01-18T12:58:42.532Z","updated_at":"2024-07-02T16:35:08.127Z","phase":"Phase 1","brief_title":"Administration of T Lymphocytes for Prevention of Relapse of Lymphomas","source_id_and_acronym":"NCT02663297","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression • ALK negative • TNFRSF8 negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression • ALK negative • TNFRSF8 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11 • ATLCAR.CD30 cell therapy"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/15/2016","start_date":" 07/15/2016","primary_txt":" Primary completion: 01/15/2021","primary_completion_date":" 01/15/2021","study_txt":" Completion: 01/01/2037","study_completion_date":" 01/01/2037","last_update_posted":"2024-04-23"},{"id":"2b050358-3cb8-4957-b9a8-e85ed3d13514","acronym":"","url":"https://clinicaltrials.gov/study/NCT04083495","created_at":"2021-01-18T19:59:38.796Z","updated_at":"2024-07-02T16:35:08.223Z","phase":"Phase 2","brief_title":"CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma","source_id_and_acronym":"NCT04083495","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • TT11 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/17/2019","start_date":" 09/17/2019","primary_txt":" Primary completion: 02/23/2028","primary_completion_date":" 02/23/2028","study_txt":" Completion: 08/01/2038","study_completion_date":" 08/01/2038","last_update_posted":"2024-04-23"},{"id":"5bbb2dd2-daf8-455a-8eda-254a2593fc7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04134325","created_at":"2021-01-18T20:11:50.668Z","updated_at":"2024-07-02T16:35:08.062Z","phase":"Phase 1","brief_title":"Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma","source_id_and_acronym":"NCT04134325","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8 • CCR4","pipe":"","alterations":" ","tags":["TNFRSF8 • CCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 07/07/2037","study_completion_date":" 07/07/2037","last_update_posted":"2024-04-23"},{"id":"d5dbb47e-aad4-4309-8d8b-fc01d9f10ce9","acronym":"LCCC 1606-ATL","url":"https://clinicaltrials.gov/study/NCT03602157","created_at":"2021-01-18T17:42:37.765Z","updated_at":"2024-07-02T16:35:08.204Z","phase":"Phase 1","brief_title":"Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL","source_id_and_acronym":"NCT03602157 - LCCC 1606-ATL","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8 • CCR4","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["TNFRSF8 • CCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bendamustine • fludarabine IV • TT11 • ATLCAR.CD30.CCR4 cells"],"overall_status":"Recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 12/12/2018","start_date":" 12/12/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2041","study_completion_date":" 09/30/2041","last_update_posted":"2024-04-23"},{"id":"b7ba30e7-e92c-4c59-8947-678e08f35152","acronym":"","url":"https://clinicaltrials.gov/study/NCT04288726","created_at":"2021-01-18T20:48:49.066Z","updated_at":"2024-07-02T16:35:16.521Z","phase":"Phase 1","brief_title":"Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas","source_id_and_acronym":"NCT04288726","lead_sponsor":"Baylor College of Medicine","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11X"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 09/16/2020","start_date":" 09/16/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2037","study_completion_date":" 06/01/2037","last_update_posted":"2024-03-04"},{"id":"c2b7af0d-ed43-45c2-88c3-a78a532de524","acronym":"","url":"https://clinicaltrials.gov/study/NCT04952584","created_at":"2021-07-07T12:53:49.491Z","updated_at":"2024-07-02T16:35:37.787Z","phase":"Phase 1","brief_title":"Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas","source_id_and_acronym":"NCT04952584","lead_sponsor":"Baylor College of Medicine","biomarkers":" ALK • TNFRSF8","pipe":" | ","alterations":" ALK positive • TNFRSF8 positive • ALK negative","tags":["ALK • TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • TNFRSF8 positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11X"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2040","study_completion_date":" 06/01/2040","last_update_posted":"2023-09-07"},{"id":"c821b744-d6ee-407a-9a85-06ffcbe3a064","acronym":"CERTAIN","url":"https://clinicaltrials.gov/study/NCT04526834","created_at":"2021-01-18T21:40:44.865Z","updated_at":"2024-07-02T16:35:50.035Z","phase":"Phase 1","brief_title":"Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04526834 - CERTAIN","lead_sponsor":"Tessa Therapeutics","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TT11"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 09/08/2021","start_date":" 09/08/2021","primary_txt":" Primary completion: 11/22/2022","primary_completion_date":" 11/22/2022","study_txt":" Completion: 03/01/2036","study_completion_date":" 03/01/2036","last_update_posted":"2023-04-20"},{"id":"5a039bc9-39b0-4a4e-8bec-0be78978180e","acronym":"CHARIOT","url":"https://clinicaltrials.gov/study/NCT04268706","created_at":"2021-01-18T20:44:27.947Z","updated_at":"2024-07-02T16:35:51.430Z","phase":"Phase 2","brief_title":"Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)","source_id_and_acronym":"NCT04268706 - CHARIOT","lead_sponsor":"Tessa Therapeutics","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • Belrapzo (bendamustine RTD) • TT11"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 02/01/2021","start_date":" 02/01/2021","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 03/01/2037","study_completion_date":" 03/01/2037","last_update_posted":"2023-04-05"},{"id":"3336dcde-07a1-4aaa-950a-9d3dd247d41a","acronym":"ACTION","url":"https://clinicaltrials.gov/study/NCT05352828","created_at":"2022-04-29T12:54:58.165Z","updated_at":"2025-02-25T14:16:54.400Z","phase":"Phase 1b","brief_title":"Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy","source_id_and_acronym":"NCT05352828 - ACTION","lead_sponsor":"Tessa Therapeutics","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • fludarabine IV • TT11"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/25/2022","start_date":" 07/25/2022","primary_txt":" Primary completion: 12/15/2025","primary_completion_date":" 12/15/2025","study_txt":" Completion: 12/15/2037","study_completion_date":" 12/15/2037","last_update_posted":"2023-04-03"},{"id":"b5420bcf-c90f-458a-84ec-96f2b1d2aa4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01316146","created_at":"2021-01-18T05:21:28.770Z","updated_at":"2024-07-02T16:35:52.766Z","phase":"Phase 1","brief_title":"Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)","source_id_and_acronym":"NCT01316146","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/03/2011","start_date":" 10/03/2011","primary_txt":" Primary completion: 01/28/2016","primary_completion_date":" 01/28/2016","study_txt":" Completion: 05/04/2022","study_completion_date":" 05/04/2022","last_update_posted":"2023-03-22"},{"id":"ee7f289f-1920-4566-a20c-7f91e8568051","acronym":"","url":"https://clinicaltrials.gov/study/NCT03049449","created_at":"2022-05-25T23:55:32.969Z","updated_at":"2024-07-02T16:35:57.446Z","phase":"Phase 1","brief_title":"T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas","source_id_and_acronym":"NCT03049449","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFA","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 03/17/2017","start_date":" 03/17/2017","primary_txt":" Primary completion: 01/26/2022","primary_completion_date":" 01/26/2022","study_txt":" Completion: 01/26/2022","study_completion_date":" 01/26/2022","last_update_posted":"2023-01-18"},{"id":"25bdc19a-f615-4b75-bbf6-347f595503e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05320081","created_at":"2022-04-11T13:52:48.178Z","updated_at":"2024-07-02T16:36:13.225Z","phase":"Phase 2","brief_title":"Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma","source_id_and_acronym":"NCT05320081","lead_sponsor":"Huazhong University of Science and Technology","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • anti-CD30 CAR T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2022-04-11"},{"id":"21ab5f18-9a9e-47b9-a96b-073643cd0b01","acronym":"","url":"https://clinicaltrials.gov/study/NCT05208853","created_at":"2022-01-26T12:53:41.471Z","updated_at":"2024-07-02T16:36:17.958Z","phase":"Phase 1","brief_title":"An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma","source_id_and_acronym":"NCT05208853","lead_sponsor":"Zhejiang University","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 02/10/2022","start_date":" 02/10/2022","primary_txt":" Primary completion: 02/10/2022","primary_completion_date":" 02/10/2022","study_txt":" Completion: 02/10/2022","study_completion_date":" 02/10/2022","last_update_posted":"2022-01-26"},{"id":"49925289-fb2e-43b6-8ef3-a1145df84116","acronym":"","url":"https://clinicaltrials.gov/study/NCT03914885","created_at":"2021-01-18T19:16:35.512Z","updated_at":"2024-07-02T16:36:19.889Z","phase":"","brief_title":"Compassionate Use Re-Infusion of ATLCAR.CD30","source_id_and_acronym":"NCT03914885","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • TT11"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2021-12-03"},{"id":"2d93897a-92db-4676-bb2c-cc518bb051b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02958410","created_at":"2021-01-18T14:32:01.244Z","updated_at":"2024-07-02T16:36:58.615Z","phase":"Phase 1/2","brief_title":"A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies","source_id_and_acronym":"NCT02958410","lead_sponsor":"Southwest Hospital, China","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression"],"overall_status":"Unknown status","enrollment":" Enrollment 45","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 10/01/2020","study_completion_date":" 10/01/2020","last_update_posted":"2019-06-25"},{"id":"f7ec00b1-9612-4461-b58e-a7754245e0c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03196830","created_at":"2021-01-18T15:45:46.880Z","updated_at":"2024-07-02T16:37:00.593Z","phase":"Phase 2","brief_title":"CAR-T for R/R B-NHL","source_id_and_acronym":"NCT03196830","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" CD20 • TNFRSF8 • CD22","pipe":"","alterations":" ","tags":["CD20 • TNFRSF8 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CAR-T CD19/CD20/CD22/CD30"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 06/01/2017","start_date":" 06/01/2017","primary_txt":" Primary completion: 05/31/2021","primary_completion_date":" 05/31/2021","study_txt":" Completion: 05/31/2021","study_completion_date":" 05/31/2021","last_update_posted":"2019-04-16"}]